Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Financial Statements
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Overview
Hangzhou Tigermed Consulting Co., Ltd. Class H's market cap is currently $4.86B. The company's EPS TTM is $-0.47; its P/E ratio is -103.48; and it has a dividend yield of 0.36%. Hangzhou Tigermed Consulting Co., Ltd. Class H is estimated to report earnings on March 29, 2027, and the estimated EPS forecast is $0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.83B | $ 6.60B | $ 7.38B | $ 7.09B | $ 5.21B |
| Gross Profit | $ 1.87B | $ 2.24B | $ 2.85B | $ 2.81B | $ 2.27B |
| Operating Income | $ 1.01B | $ 664.42M | $ 2.49B | $ 2.58B | $ 1.92B |
| EBITDA | $ 1.42B | $ 1.13B | $ 2.91B | $ 2.93B | $ 3.90B |
| Net Income | $ 887.89M | $ 405.14M | $ 2.02B | $ 2.01B | $ 2.87B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.84B | $ 2.13B | $ 7.46B | $ 7.88B | $ 8.57B |
| Total Assets | $ 28.36B | $ 28.67B | $ 29.68B | $ 27.45B | $ 23.74B |
| Total Debt | $ 1.47B | $ 2.63B | $ 2.83B | $ 2.80B | $ 1.19B |
| Net Debt | $ -302.82M | $ 579.64M | $ -4.59B | $ -5.06B | $ -7.35B |
| Total Liabilities | $ 4.10B | $ 4.61B | $ 5.23B | $ 4.77B | $ 3.14B |
| Stockholders' Equity | $ 20.96B | $ 20.67B | $ 21.03B | $ 19.58B | $ 18.12B |
| Cash Flow | |||||
| Free Cash Flow | $ 903.72M | $ 740.45M | $ 836.68M | $ 908.90M | $ 1.06B |
| Operating Cash Flow | $ 1.12B | $ 1.10B | $ 1.15B | $ 1.36B | $ 1.42B |
| Investing Cash Flow | $ 491.56M | $ -4.74B | $ -1.53B | $ -2.79B | $ -2.78B |
| Financing Cash Flow | $ -1.93B | $ -1.70B | $ -7.81M | $ 809.25M | $ -163.09M |
Currency in CNY
